This past week there has been swirling comment about bonuses on Wall Street, and my suburban Connecticut friends have been telling me about AIG neighbors who are feeling alternately angry, insecure, or shamed. I agree the system of bonuses was all wrong and that Wall Street types have to get connected to the real world the rest of us live in. And yes, I think a lot of these people who work or worked at companies virtually "owned" by us taxpayers should give the money back.

I understand investment bankers and others are under pressure to make millions for investors and themselves - fast. And they expect a big personal return in the short-term, even if someone else is left holding the bag – like the world economy, in the current case, later on. That's pure personal greed, of course, and that has to be regulated and even criminalized, if possible, when so much is at stake.

I was troubled last week when a friend, at lunch, told me his 20-something son, living in New York City as a beginning investment banker, was angry about the public outcry about bonuses. He had envisioned making millions at a young age and now fears his hedonistic lifestyle may be in jeopardy. Neither his father nor I had any sympathy for him.

We need a new day in the financial world.

Happily, for a variety of reasons, I think we have the prospect of a new day in the healthcare world – especially when it comes to at least some pharmaceutical companies doing the right thing long-term rather than just pushing short-term sales.

Many of the pharma product managers I have met over the years have been young MBA types who knew they were measured by sales gains in the short-term. They rushed to do questionable television ads and expensive promotion campaigns recommended by their agencies. The agencies made money, maybe sales bumped up, but did patients really do better long-term? One problem, of course, is that typically, most of the people involved in funding or executing these campaigns do not know many people afflicted with the conditions their products treat. Like the investment bankers, many move in the big city world of business entertainment and the insular world of corporate politics were few people are sick – at least outwardly.

But, things might be changing. First, drug companies are on the bubble. They are not much more popular than Wall Street and like with our financial future, we depend upon pharma for a critical part of our lives - our health future. Most families have someone who takes a daily medicine.

So in this time of "patient empowerment" and the Obama administration trying to cut billions in healthcare costs, pharma has the opportunity to make a long-term commitment to better health through education and support rather than through blatant product marketing. I would welcome doing away with TV ads for drugs and having those same companies support education and yes, prevention, in the therapeutic areas where they have products. My hope is the young product managers, with guidance from their more senior superiors, understand the public is activated now more than ever. So is government. There is ample opportunity to be the pharma corporate "good guy. But little patience for the splashy drug promotion and high pricing of the past.

Later this week I go before a panel of pharma marketers. They reached out to me in their quest to support new patient programs. I am excited this may be is a sign of a new day and welcome the opportunity to tell our story. I believe when leading pharma companies support education and empowerment patients better understand the leading products that can help and make their own commitment to make them part of their treatment or prevention plan long-term.

My hope is in the financial world and the healthcare world, the business decision-makers will now understand they truly win when they do the right thing not putting themselves first, but putting us first.

Wishing you and your family the best of health,

Andrew